deferoxamine has been researched along with Parkinsonian Disorders in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine (DFO) has shown therapeutic promise for the treatment of Parkinson׳s disease (PD) as it has reduced both behavioral and biochemical deficits when injected into the brain of rodent models of PD." | 1.40 | Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease. ( Arneson, LC; Crow, JM; Faltesek, KA; Fine, JM; Forsberg, AC; Frey, WH; Hanson, LR; Mohan, KG; Renner, DB; Wong, JC, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fine, JM | 1 |
| Forsberg, AC | 1 |
| Renner, DB | 1 |
| Faltesek, KA | 1 |
| Mohan, KG | 1 |
| Wong, JC | 1 |
| Arneson, LC | 1 |
| Crow, JM | 1 |
| Frey, WH | 1 |
| Hanson, LR | 1 |
| Dexter, DT | 1 |
| Statton, SA | 1 |
| Whitmore, C | 1 |
| Freinbichler, W | 1 |
| Weinberger, P | 1 |
| Tipton, KF | 1 |
| Della Corte, L | 1 |
| Ward, RJ | 1 |
| Crichton, RR | 1 |
| Junxia, X | 1 |
| Hong, J | 1 |
| Wenfang, C | 1 |
| Ming, Q | 1 |
| Zhang, X | 1 |
| Xie, W | 1 |
| Qu, S | 1 |
| Pan, T | 1 |
| Wang, X | 1 |
| Le, W | 1 |
| Lin, AM | 1 |
| Jiang, H | 1 |
| Chen, WF | 1 |
| Xie, JX | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease[NCT01539837] | Phase 2 | 22 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess whether Deferiprone therapy directly affects the symptoms of Parkinson's disease, modify regional brain mineralization (iron concentration) as assessed with T2* MRI in PD patients in the dentate nucleus. In previous animal studies, Deferiprone treatment reduced dentate nucleus iron content, as assessed by MRI. An increase in the T2*MRI value represents an increase in mineralization. (NCT01539837)
Timeframe: 6 months
| Intervention | ms (Mean) |
|---|---|
| Placebo | 30.74 |
| Deferiprone 20mg | 30.59 |
| Deferiprone 30mg | 29.86 |
To assess whether there were any serious adverse events in 6-month treatment with Deferiprone. (NCT01539837)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| Deferiprone 20mg | 0 |
| Deferiprone 30mg | 0 |
6 other studies available for deferoxamine and Parkinsonian Disorders
| Article | Year |
|---|---|
Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Apomorphine; Deferoxamine; Dopamine Agoni | 2014 |
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.
Topics: Animals; Benzoates; Brain; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Immunohistochemist | 2011 |
Dopamine release rather than content in the caudate putamen is associated with behavioral changes in the iron rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Caudate Nucleus; Chlorides; Deferoxamine; Disease Models, An | 2003 |
Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.
Topics: Acetylcysteine; Animals; Deferoxamine; Iron Chelating Agents; Male; Mice; Mice, Inbred C57BL; Nerve | 2005 |
Coexistence of zinc and iron augmented oxidative injuries in the nigrostriatal dopaminergic system of SD rats.
Topics: Anesthesia; Animals; Brain; Corpus Striatum; Deferoxamine; Dopamine; Drug Interactions; Glutathione; | 2001 |
[Relationship between dopamine and iron contents in the brain of parkinsonian rats].
Topics: Animals; Brain; Caudate Nucleus; Deferoxamine; Disease Models, Animal; Dopamine; Female; Iron; Neuro | 2001 |